Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
Actinobacillus pleuropneumoniae is the causative agent of acute and chronic pleuroneumonia that is responsible for substantial morbidity and mortality in the pig industry. New improved vaccines that can protect against all serotypes and prevent colonization are required. In a previous study we showed that whole cells of Propionibacterium acnes protected pigs from A. pleuropneumoniae serotype 1 and 5 and, therefore, the basis for a promising heterologous vaccine. The aim of this study was to identify those protein antigens of P. acnes responsible for protection against A. pleuropneumoniae infection. Six P. acnes protein antigens that were recognized by sera raised against A. pleuropneumoniae were identified by 2-DE and immunoblotting. Recombinant versions of all P. acnes proteins gave partial protection (10-80%) against A. pleuropneumoniae serotype 1 and/or 5 infection in a mouse challenge model. The best protection (80% serotype 1; 60% serotype 5) was obtained using recombinant P. acnes single-stranded DNA-binding protein. In part, protection against A. pleuropneumoniae infection may be mediated by small peptide sequences present in P. acnes single-stranded DNA-binding protein that are cross-reactive with those present in the A. pleuropneumoniae-specific RTX toxin ApxIV and the zinc-binding protein ZnuA. The results suggest that P. acnes may be a useful vaccine to protect against different serotypes of A. pleuropneumoniae.
College of Animal Science and Veterinary Medicine, Jinlin University, Changchun 130062, PR China; Section of Paediatrics, Imperial College London, St. Mary's Campus, London W2 1PG, United Kingdom.
Linxi
L
Li
Changjiang
C
Sun
Feng
F
Yang
Shuxin
S
Yang
Xin
X
Feng
Jingmin
J
Gu
Wenyu
W
Han
Paul R
PR
Langford
Liancheng
L
Lei
D000189:Actinobacillus Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000276:immunology*; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology* / Q000302:isolation & purification; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D004195:Disease Models, Animal; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D015151:Immunoblotting; D051379:Mice; D008807:Mice, Inbred BALB C; D011425:Propionibacterium acnes / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D016019:Survival Analysis; D013552:Swine; D013553:Swine Diseases / Q000276:immunology* / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic
Actinobacillus pleuropneumoniae; Heterologous immunization; MALDI-ToF mass spectrometry; Propionibacterium acnes; Vaccine